$8 billion Sobi takeover shows orphan drug IP assets are in high demand
The acquisition of the rare disease specialist is latest development in the booming orphan drug deals market
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.